XORTX Therapeutics Company Description

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada.

It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.

The company is based in Calgary, Canada.

XORTX Therapeutics Inc.

Country	Canada
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Allen Davidoff

Contact Details

Address: 3710 - 33rd Street NW Calgary, AB T2L 2M1 Canada
Phone	403-455-7727
Website	xortx.com

Stock Details

Ticker Symbol	XRTX
Exchange	TSX Venture Exchange
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	CA98420Q2071
SIC Code	2834

Key Executives

Name	Position
Dr. Allen Warren Davidoff Ph.D.	Founder, Chief Executive Officer, President and Director
Dr. Michael Scott Bumby D.V.M., M.B.A.	Chief Financial Officer
Dr. Stephen Haworth M.D., MRCP	Chief Medical Officer
Dr. Stacy Evans M.B.A., M.D.	Chief Business Officer
Nick Rigopoulos	Director of Communications
Dr. David Sans M.B.A., Ph.D.	Director of Corporate Development
Dr. David MacDonald Ph.D.	Consultant of Clinical Operations
Charlotte May	Corporate Secretary